

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 09/648,864
Filing Date August 25, 2000
First Named Inventor Howard M. Johnson
Group Art Unit 1646
Examiner Name Janet Andres, Ph.D.
Attorney Docket Number UF-243X

Sheet 1 of

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
↓	R1	DUSHEIKO, G. M. et al. "Recombinant Leucocyte Interferon Treatment of Chronic Hepatitis B" <i>Journal of Hepatology</i> , 1986, pp. S199-S207, Vol. 3 (Suppl. 2), Elsevier Science Publishers Biomedical Division.
	R2	KHAN, O. A. et al. "Immunomodulating Functions of Recombinant Ovine Interferon Tau: Potential for Therapy in Multiple Sclerosis and Autoimmune Disorders" <i>Multiple Sclerosis</i> , 1998, pp. 63-69, Vol. 4, Stockton Press.
	R3	KIMATA, H. et al. "Interferon-Alpha Treatment for Severe Atopic Dermatitis" <i>Allergy</i> , 1995, pp. 837-840, Vol. 50.
	R4	NOH, G. W. and LEE, K. Y. "Blood Eosinophils and Serum IgE as Predictors for Prognosis of Interferon-gamma Therapy in Atopic Dermatitis" <i>Allergy</i> , 1998, pp. 1202-1207, Vol. 53.
	R5	
	R6	
	R7	
	R8	
	R9	
	R10	
	R11	
	R12	
	R13	

Examiner Signature

Date

Considered

10/17/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.